Use of guanfacine in the treatment of behavioral disorders
DCFirst Claim
Patent Images
1. A method of treating a behavioral disinhibition in a primate without inducing excessive sedation, comprisingadministering to the primate a behavior inhibiting dose of guanfacine, wherein the dose ranges between 0.01 mg/kg of body weight and 0.86 mg/kg of body weight.
2 Assignments
Litigations
0 Petitions
Accused Products
Abstract
Disclosed is a method of treating disorders which have prominent symptoms of behavioral disinhibition (e.g., Attention-Deficit Hyperactivity Disorder, Conduct Disorder, Oppositional Defiant Disorder, Tourette'"'"'s Syndrome, Lesch-Nyhan Syndrome, or the disinhibitory symptoms accompanying Post-traumatic Stress Disorder or dementia) in a primate with minimal sedative side effects by administering thereto a therapeutically effective amount of guanfacine.
-
Citations
12 Claims
-
1. A method of treating a behavioral disinhibition in a primate without inducing excessive sedation, comprising
administering to the primate a behavior inhibiting dose of guanfacine, wherein the dose ranges between 0.01 mg/kg of body weight and 0.86 mg/kg of body weight.
-
7. A method of inhibiting a disinhibitory behavior in a primate without inducing excessive sedation, comprising:
administering to the primate a behavior inhibiting dose of guanfacine, wherein the dose ranges between 0.01 mg/kg of body weight and 0.86 mg/kg of body weight. - View Dependent Claims (8, 9, 10, 11, 12)
Specification